Login to Your Account

Somaxon's Silenor Gains FDA Nod in Crowded Insomnia Market

By Jennifer Boggs

Friday, March 19, 2010
Shares of Somaxon Pharmaceuticals Inc. more than doubled after the FDA approved its insomnia drug Silenor (doxepin), marking a major achievement for the San Diego-based firm, which entered 2010 with just over $5 million in the bank and a sole pipeline candidate that regulators had twice rejected. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription